Cuen-Lara E, Reyes-Torres G, Palacios-Solís DA

Language: Spanish
References: 22
Page: 144-149
PDF size: 332.49 Kb.

ABSTRACT

Denosumab-induced osteonecrosis is a possible side effect of up to 15% in patients using this drug, which is mainly indicated to treat bone problems related to osteoporosis or malignant neoplasms. Its onset and treatment can be complex because it can sometimes be underdiagnosed, causing the disease to progress. Treatment can range from conservative means to invasive procedures. This article presents a clinical case of a patient with denosumab-induced osteonecrosis after bone extraction. Despite presenting purulent exudate and signs of infection, the patient was treated and resolved conservatively with antibiotic therapy and chlorhexidine to subsequently remove the bone sequestration, highlighting the importance of timely follow-up and adherence, avoiding morbid procedures.

REFERENCES

1. Tofé VI, Bagán L, Bagán JV. Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases. J Clin Exp Dent. 2020; 12 (7): e676-e681.

2. Wick A, Bankosegger P, Otto S, Hohlweg-Majert B, Steiner T, Probst F, et al. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clin Oral Investig. 2022; 26 (3): 2839-2852.

3. Limones A, Sáez-Alcaide LM, Díaz-Parreño SA, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020; 25 (3): e326-e336.

4. Zhang C, Shen G, Li H, Xin Y, Shi M, Zheng Y, et al. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis. Spec Care Dentist. 2024; 44 (2): 530-541.

5. Aoki K, Matsunaga S, Ito S, Shibahara T, Nomura T, Matsuzaki H, et al. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis. J Bone Miner Metab. 2021; 39 (5): 737-747.

6. Palla B, Burian E, Deek A, Scott C, Anderson J, Callahan N, et al. Comparing the surgical response of bisphosphonate-related versus denosumab-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2021; 79 (5): 1045-1052.

7. Miyoshi T, Otsuru M, Morishita K, Omori K, Miura KI, Hayashida S, et al. Differences between medication-related osteonecrosis of the jaw caused by bisphosphonates and denosumab: histological, molecular biological, and clinical studies. Cureus. 2024; 16 (6): e62855.

8. Ehrenstein V, Heide-Jorgensen U, Schiodt M, Akre O, Herlofson BB, Hansen S, et al. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden. Cancer. 2021; 127 (21): 4050-4058.

9. Pichardo SEC, Broek FWT, Fiocco M, Appelman-Dijkstra NM, van Merkesteyn JPR. A comparison of the cone beam computed tomography findings in medication-related osteonecrosis of the jaws related to denosumab versus bisphosphonates: an observational pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020; 129 (4): 411-417.

10. Assili Z, Dolivet G, Salleron J, Griffaton-Tallandier C, Egloff-Juras C, Phulpin B. A comparison of the clinical and radiological extent of denosumab (Xgeva^®) related osteonecrosis of the jaw: a retrospective study. J Clin Med. 2021; 10 (11): 2390.

11. Kang JY, Kim SY, Lim JS, Kim JY, Jin GY, Lee YJ, et al. Denosumab-associated jaw bone necrosis in cancer patients: retrospective descriptive case series study. Maxillofac Plast Reconstr Surg. 2023; 45 (1): 23.

12. Okuma S, Matsuda Y, Nariai Y, Karino M, Suzuki R, Kanno T. A retrospective observational study of risk factors for denosumab-related osteonecrosis of the jaw in patients with bone metastases from solid cancers. Cancers (Basel). 2020; 12 (5): 1209.

13. Liu FC, Luk KC, Chen YC. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan. Osteoporos Int. 2023; 34 (10): 1729-1737.

14. Colella A, Yu E, Sambrook P, Hughes T, Goss A. What is the risk of developing osteonecrosis following dental extractions for patients on denosumab for osteoporosis? J Oral Maxillofac Surg. 2023; 81 (2): 232-237.

15. Komatsu Y, Kawai T, Hirano T, Hoshi I, Yamaya G, Ogawa A, et al. Risk factors of medication-related osteonecrosis of the jaw: A clinical investigation. J Stomatol Oral Maxillofac Surg. 2024; 125 (6): 101791.

16. Jung S, Kim J, Park JH, Kim KY, Kim HJ, Park W. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients. Sci Rep. 2022; 12 (1): 8641.

17. Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, et al. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer. 2022; 30 (3): 2341-2348.

18. Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, Hauselmann H, et al. Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Miner Res. 2022; 37 (2): 340-348.

19. Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, et al. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol. 2021; 87 (6): 871-877.

20. Fu PA, Shen CY, Yang SR, Lee CH, Chen HW, Lai EC, et al. Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw. Sci Rep. 2023; 13 (1): 8403.

21. Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, et al. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer. 2021; 29 (8): 4763-4772.

22. Bracchi P, Zecca E, Brunelli C, Miceli R, Tine G, Maniezzo M, et al. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with denosumab. Cancer Med. 2023; 12 (17): 18317-18326.